Upload
bertina-bishop
View
215
Download
0
Embed Size (px)
Citation preview
Symptom Distress During Breast Cancer Chemotherapy
Does Race Matter?
Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP
Associate Professor
University of Pittsburgh School of NursingFunding•American Cancer Society, RSGT-09-150-01-CPHPS•Preliminary Work
•NCI-KO7 CA 100 588 (03-08)•Susan G. Komen Foundation, POP33008•Center for Research University of Pittsburgh School of Nursing
Background• AA women have worse survival disparity
than white women in breast cancer.
• Multifactorial: Environment, Patient and Provider– More under-dosing secondary to BMI or co-
morbidities.
Under-Dosing?• AA patients with cancer including AA women with breast
cancer historically experience greater chemotherapy related symptom distress than white women.
–Chemo is held, decreased or discontinued with symptom distress
Specific Aims1. Determine the cumulative and individual symptom distress of women during
breast cancer chemotherapy.2. Compare the cumulative and individual
symptom distress of women during breast cancer chemotherapy according to race.
SampleStarting January 1, 2010 - December 31,2011
All AA women receiving chemotherapy with matched white sample.
One urban cancer center with routine symptom assessment and distress screening.
Design
• Retrospective chart review
• Matched pair analysis
• Matched white women 1:1 for age and stage– Excel to SPSS v.20
Instrument
The 9 item Edmonton Symptom Assessment Scale is used in routine clinic practice as a patient symptom reporting tool.
Potential score is 0-90. Higher scores indicate worse distress.
The incidence and severity of symptoms were measured at baseline and each chemotherapy administration visit.
Total Chemotherapy Visits
• 240 visits for AA women – (mean 7.7 chemo visits/patient)
• 250 visits for W women– (mean 7.6 chemo visits/patient).
Mean Symptom Scores
Total Mean ESAS Scores were worse during chemotherapy for AA than white women.
Mean Scores AA (n=28)
White (n=28)
P value
At Baseline 9.4/ 12.8 8.6/12.5 p=.131
Total 12.7/ 8.3/ P=.001
Disparity in Specific Symptoms• Total mean scores for 4 of the 9
symptoms over the course of chemotherapy.AA White P value
Nausea Mean/SD1.26/2.4
Mean/SD.4/1.4
P=.000
Appetite Mean/SD1.14/2.2
Mean/SD.3/.9
P=.000
Shortness of Breath
Mean/SD.90/1.8
Mean/SD.24/.72
P=.000
Fatigue Mean/SD 3.2/3.2
Mean/SD2.1/2.5
P=.000
Chemotherapy Dose Reduction• White - 1/28 white patients dose
reduced, no early cessation.
• African American - 1/28 patients dose reduced, 3/28 AA patients had early chemotherapy cessation
Conclusions• Overall symptom distress and
specific symptoms during breast cancer chemotherapy are worse for AA women than matched White controls.
• Clinical significance is unknown.
Conclusion
• This awareness can help nurses provide targeted anticipatory guidance and preventative measures in order to decrease symptom burden, and possibly prevent chemotherapy dose reduction and early treatment cessation.